OBI PHARMA, INC.
Booth No: L232
OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI’s mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (incl. Globo H, SSEA3, SSEA4) and AKR1C3, which are highly expressed in multiple cancers. The company's novel first-in-class oncology portfolio includes adagloxad simolenin, OBI-888, OBI-999, OBI-898, OBI-866 and OBI-3424.
Exhibitors you may be interested in